2004-0020-Geng
the Office of Technology Management at The University of Texas Health Science Center at Houston
   Search
  
blue arrows Technologies
blue arrows Forms / Agreements
blue arrows UT System Intellectual Property
blue arrows Intellectual Property Committee
blue arrows Technology Management Home
spacer
blue arrows Contact Information
blue arrows Maps



spacer
 Office of Research
spacer
 EVP for Research
spacer
 Laboratory Animal Medicine/Care
spacer
 Environmental Health & Safety
spacer
 Genomics/Proteomics Core Labs
spacer
 Human Subjects Research
spacer
 Sponsored Projects
spacer
 


 NOVEL COMPOSITIONS AND METHODS  FOR USING  A BIOACTIVE PROTEIN TO INHIBIT APOPTOSIS AND INFLAMMATION IN STEM CELLS AND CARDIAC TISSUES

 Market:  About one million Americans die of heart disease each year, and it was estimated that over 13 million US citizens have cardiovascular disease.  Peripheral artery disease is expected to effect 23 million people in developed countries by 2012 (Datamonitor).  Atherosclerotic coronary artery disease is the number one cause of death in the US, and as such, the demand for therapeutics in this area is extreme.

Competitors and Current Problems:  Surgeries and drug interventions used to address heart muscle damaged by heart disease is not only expensive, but often not curative.  In critical situations where heart transplant is needed, the wait list is long with donors in short supply.  The best of all possibilities is for the damaged heart to actually heal.

The Technology:   Scientists at the University of Texas Health Science Center at Houston discovered a protein that is capable of regulating apoptosis and protect against inflammatory or oxidative injury. This unique protein, in its recombinant version or biologically active peptides, is effective at treating or preventing atherosclerosis-associated tissue damages, including aneurisms, and deterring or preventing stress response in transplanted stem cells, cardiac myocytes, vascular stem cells, and vascular smooth muscle cells.  Included in the technology is use of stem cells for heart delivery and research tools such as transgenic mice.  Data includes induced expression of the gene in tissue culture, synthesis of intracellular and secret forms of the protein, diagnostic kit development, activity showing the expressed gene induces downstream genes, and characterization of the transgenic mice.

 

NON-CONFIDENTIAL TECHNOLOGY DESCRIPTION

The preceding is intended to be a non-confidential summary of a novel technology created at the University of Texas Health Science center at Houston (UTHSCH), for which the University has obtained patent protection. 

UTHSCH Ref. No. 2004-0025

Inventors: Drs. Geng and Willerson

Patent Status: Pending

License Available: world-wide; exclusive or non-exclusive

 

To obtain further information about this technology, please contact:
Office of Technology Management, 7000 Fannin, Suite 720, Houston, TX 77030
Phone: (713) 500-3369  Fax: (713) 500-0331
Email: uthsch-otm@uth.tmc.edu


Valid HTML 4.01! Valid CSS!

Link to the UTHSCH home page Office of Research link Hyperlink to The Center for Laboratory Animal Medicine and Care